Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LYR-220 Design 1 · 1 trial · 2 indications
Product-related unexpected serious adverse events
Plasma MF concentrations at 1 hour post study treatment administration and at Days 2 or 3, days 5 or 8, and Weeks 4,12,16 or 20, 24 and 25. The PK analysis will be performed based on subjects with available plasma MF concentration data post Day 1 administration procedure.
| Arm | Type | Description |
|---|---|---|
| Part 1: Treatment Arm LYR-220 Design 1 | EXPERIMENTAL | Bilateral insertion of LYR-220 drug matrix (mometasone furoate 7500 µg) Design 1 |
| Part 1 and Part 2: Treatment Arm LYR-220 Design 2 | EXPERIMENTAL | Bilateral insertion of LYR-220 drug matrix (mometasone furoate 7500 µg) Design 2 |
| Part 2: Treatment Arm Bilateral sham procedure control | SHAM_COMPARATOR | Bilateral sham procedure control |
| Name | Type | Description |
|---|---|---|
| LYR-220 Design 1 (Part 1 only) | DRUG | LYR-220 drug matrix (mometasone furoate 7500 µg) Design 1 |
| LYR-220 Design 2 (Part 1 and Part 2) | DRUG | LYR-220 drug matrix (mometasone furoate 7500 µg) Design 2 |
| Bilateral sham procedure control (Part 2) | DRUG | Bilateral sham procedure control |
Inclusion Criteria: * Diagnosis of chronic rhinosinusitis. * Has had a prior bilateral total ethmoidectomy. * Has computed tomography (CT) ethmoid cavity opacification. * Has a Sinonasal Outcome Test (SNOT-22) ≥ 20 at Screening Visit. * Minimum cardinal symptom score. * Has been informed of the nat...
Top 3 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 4 | PHASE3 | Itepekimab, Lunsekimig |
| AstraZeneca PLC | AZN | 4 | PHASE3 | Tezepelumab |
| Eli Lilly and Company | LLY | 1 | PHASE3 | LY3650150 |
LYR-220 Design 1 is an investigational therapy being studied for chronic sinusitis, including chronic rhinosinusitis. It is a small molecule developed by Lyra Therapeutics, Inc. and has completed a Phase 2 clinical trial in adults with this condition.
LYR-220 Design 1 is being developed by Lyra Therapeutics, Inc., a biotechnology company whose common stock trades on the Nasdaq under the ticker symbol LYRA. The company is responsible for the clinical development of this investigational product.
LYR-220 Design 1 is in Phase 2 clinical development. The only reported trial for this asset is a completed Phase 2 study, and no active trials are currently listed. It remains an investigational therapy and has not been approved by the FDA.
LYR-220 Design 1 has been evaluated in one clinical trial: the Phase 2 BEACON study, registered as NCT05035654. Titled "LYR-220 for Adult Subjects With Chronic Rhinosinusitis," the trial enrolled 48 adults, was randomized and sham-controlled, and has been completed.
Yes, LYR-220 Design 1 is also referred to as LYR-220 Design 1 (Part 1 only). This alternative name may appear in study documentation or discussions, but it refers to the same investigational small molecule for chronic sinusitis.